Volition Sponsors Upcoming GenomeWeb Webinar

Rhea-AI Summary

VolitionRx (NYSE AMERICAN: VNRX) announces sponsorship of a GenomeWeb webinar titled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" scheduled for October 8, 2025.

The webinar will feature presentations from Dr. Eric Ariazi, discussing epigenetic pathways and cancer immunoediting, and Dr. Marielle Herzog, R&D director at Belgian Volition, who will present case studies on Nu.Q® assays. The event aims to showcase Volition's Nu.Q® Discover service for drug developers and scientists, focusing on epigenetic profiling in disease model development and clinical studies.

HENDERSON, Nev., Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entitled "Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery" on Wednesday, October 8 (details can be found below).

Dr. Jasmine Kway, Chief Executive Officer, Singapore Volition, said:

"This webinar will showcase our Nu.Q® Discover service and how it provides drug developers and scientists a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies."

Details of the Webinar: Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery

Registration Link

Date : Wednesday October 8

Time: 8am PT / 11am ET / 5pm CET

Speakers : Dr Eric Ariazi and Dr Marielle Herzog

Webinar Abstract:

In this webinar, translational cancer biologist Eric Ariazi will provide an overview of major epigenetic pathways, highlighting their roles in health and disease. He will use EZH2 and EED, subunits in the PRC2 (polycomb repressor complex 2), as a case study in cancer immunoediting, discussing the preclinical and clinical studies of current pharmacologic PRC2/EZH2/EED inhibitors and the prospects for EZH2 inhibitors and immunotherapy combination for cancer treatment.

Marielle Herzog, R&D director at Belgian Volition, will provide further case studies and insights on the simple, robust Nu.Q assays that have been developed according to CLSI guidelines. She'll discuss work on a variety of sample matrices to demonstrate how these tools have the potential to contribute to disease research and clinical development, offering a useful resource in epigenetics.

About Nu.Q® Discover

Volition's Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready.

Nu.Q® Discover is built on proprietary nucleosome quantification technology. It is a valuable research tool for R&D professionals working within the field of pharmaco-epigenetics, studying the epigenetic basis for variation in response to drugs.

About Volition

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. 

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.

Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/volition-sponsors-upcoming-genomeweb-webinar-302573570.html

SOURCE VolitionRx Limited

FAQ

When is VolitionRx (VNRX) hosting the GenomeWeb webinar in October 2025?

The webinar is scheduled for Wednesday, October 8, 2025 at 8am PT / 11am ET / 5pm CET.

What will be discussed in the VNRX GenomeWeb webinar?

The webinar will cover epigenetic modifications for biomarker and drug discovery, featuring discussions on epigenetic pathways, cancer immunoediting, and Nu.Q® assays for disease research.

Who are the speakers at the VolitionRx October 2025 webinar?

The speakers are Dr. Eric Ariazi, who will discuss epigenetic pathways and cancer immunoediting, and Dr. Marielle Herzog, R&D director at Belgian Volition, who will present Nu.Q® assay case studies.

What is the purpose of Volition's Nu.Q® Discover service?

Nu.Q® Discover provides state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies for drug developers and scientists.